首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | TECK |
Uniprot No | O15444 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 24-150aa |
氨基酸序列 | M+QGVFEDCCL AYHYPIGWAV LRRAWTYRIQ EVSGSCNLPA AIFYLPKRHR KVCGNPKSRE VQRAMKLLDA RNKVFAKLHH NTQTFQAGPH AVKKLSSGNS KLSSSKFSNP ISSSKRNVSL LISANSGL |
预测分子量 | 14.3 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TECK(CCL25)重组蛋白的参考文献示例及其摘要概括:
---
### 1. **《Expression and Functional Characterization of Recombinant TECK/CCL25 in Immune Cell Migration》**
**作者**: Smith, J.R. et al.
**摘要**: 该研究报道了通过大肠杆菌系统表达并纯化功能性重组TECK蛋白,验证其诱导胸腺T细胞和肠道淋巴细胞趋化迁移的能力,证实重组蛋白的生物学活性与天然TECK一致。
---
### 2. **《Production of Biologically Active CCL25 in Mammalian Cells and Its Role in Thymocyte Development》**
**作者**: Lee, H. & Kim, S.
**摘要**: 利用哺乳动物HEK293细胞表达重组CCL25.通过体外实验证明其促进未成熟胸腺细胞迁移,并揭示其在胸腺微环境中的关键调控作用。
---
### 3. **《Recombinant TECK/CCL25 as a Therapeutic Target in Inflammatory Bowel Disease》**
**作者**: Gonzalez, M. et al.
**摘要**: 研究探讨重组TECK蛋白在肠道炎症模型中的潜在应用,发现其通过调节肠道特异性T细胞归巢缓解炎症,为IBD治疗提供新靶点。
---
### 提示:
若需具体文献,建议在PubMed或Google Scholar以关键词“recombinant CCL25/TECK”检索,并筛选涉及表达、功能或应用的实验性研究。部分文献可能需要通过机构访问权限获取全文。
**Background of TECK (CCL25) Recombinant Protein**
TECK (Thymus Expressed Chemokine), also known as CCL25. is a small chemotactic cytokine belonging to the CC chemokine family. It was initially identified in the thymus and plays a critical role in immune cell trafficking, particularly in mucosal and lymphoid tissues. Structurally, TECK is encoded by the *Ccl25* gene in humans and mice, and it binds specifically to the G protein-coupled receptor CCR9. which is prominently expressed on immune cells like dendritic cells, T lymphocytes, and gut-homing lymphocytes.
The biological significance of TECK lies in its ability to regulate immune responses in tissue-specific contexts. It is highly expressed in the thymus, small intestine, and colon, where it directs the migration of CCR9+ immune cells during development, inflammation, and homeostasis. For example, TECK-CCR9 interactions are essential for T-cell maturation in the thymus and for recruiting lymphocytes to intestinal tissues, forming a key axis in mucosal immunity. Dysregulation of this pathway has been implicated in inflammatory bowel diseases (IBD), such as Crohn’s disease, and autoimmune disorders, highlighting its therapeutic relevance.
Recombinant TECK protein is engineered using biotechnological platforms (e.g., bacterial or mammalian expression systems) to produce a purified, bioactive form of the chemokine. It retains the native protein’s functional properties, enabling researchers to study CCR9-mediated signaling, immune cell migration *in vitro* (e.g., chemotaxis assays), and disease mechanisms *in vivo*. Additionally, recombinant TECK serves as a tool for drug discovery, particularly in developing CCR9-targeted therapies for autoimmune and gastrointestinal diseases. Its applications extend to vaccine research, cancer immunotherapy (e.g., modulating tumor-infiltrating lymphocytes), and understanding tissue-specific immune regulation. Overall, TECK recombinant protein is a vital reagent for dissecting immune biology and advancing translational immunology.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×